Center for Outcomes Research in Liver Diseases, 2411 I Street NW, Washington, DC 20037, USA; Betty and Guy Beatty Center for Integrated Research, Inova Health System, 3300 Gallows Road, Falls Church, VA 22042, USA.
Center for Outcomes Research in Liver Diseases, 2411 I Street NW, Washington, DC 20037, USA; Betty and Guy Beatty Center for Integrated Research, Inova Health System, 3300 Gallows Road, Falls Church, VA 22042, USA; Department of Medicine, Center for Liver Diseases, Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042, USA.
Clin Liver Dis. 2017 Aug;21(3):579-594. doi: 10.1016/j.cld.2017.03.012. Epub 2017 Apr 22.
The economic burden of chronic hepatitis C might exceed $10 billion annually in the United States alone. This disease has a worldwide prevalence of up to 3%, making the global burden of the disease comparably tremendous. The cost of the disease includes direct medical expenses for its hepatic and extrahepatic manifestations, and also indirect costs incurred from impaired quality of life and the loss of work productivity. Recent emergence of treatment options that are not only highly effective and safe but also costly has emphasized the need to study the disease from the economic point of view.
仅在美国，慢性丙型肝炎的经济负担每年可能超过 100 亿美元。这种疾病在全球的患病率高达 3%，因此疾病的全球负担同样巨大。该病的费用包括其肝脏和肝外表现的直接医疗费用，以及生活质量受损和工作生产力丧失带来的间接费用。最近出现的不仅高效、安全而且昂贵的治疗方案强调了从经济学角度研究该病的必要性。
